In persons with type 2 diabetes treated with multiple daily insulin injections, liraglutide increased insulin secretion, measured by C-peptide, by 19% versus placebo after 24 weeks.
In plain wordsIn people with type 2 diabetes on insulin injections, liraglutide raised the body's insulin output (C-peptide) by 19% compared with placebo.
- Peptide
- Liraglutide
- Outcome
- IncreaseC-peptide (insulin secretion) after 24 weeks
- Study
n: not reported in source
- Comparator
- Placebo
- Outcome group
- Glycemic control · Metabolic and weight
- Studied dose
- Dose not stated · 24 weeksAs given in this study (human).
Measurements
- C-peptide increase
- 19%
- liraglutide, 24 weeks
Source sentences
Liraglutide increased insulin secretion, measured by C-peptide, by 19% after 24 weeks of treatment.
1 context sentence(design, population, supporting numbers)
In this post-hoc analysis of data from a randomised clinical trial, we compared the effect of liraglutide to placebo on markers of insulin secretion in persons with type 2 diabetes treated with multiple daily insulin injections.